Eng
Without a doubt, the cell therapy industry is coming of age. In addition to growing numbers of cell therapy clinical trials, there are 17 cell therapy products that have been approved worldwide and 140+ cell therapy companies competing in the global marketplace. These metrics are extremely important, because they indicate that the market for cell therapy products is expanding.
However, one of the most telling trends within the industry is a growing interest among “big pharma” in cell therapy companies. At its core, this is a strategic way for pharmaceutical companies to diversity their product development pipeline.
Recently, the pharmaceutical industry has been accelerating investment into cell therapy companies. Examples of this include:
Much of this partnering activity has been supported by accelerated regulatory pathways that have been passed in major healthcare markets worldwide, including the U.S., Japan, and South Korea. In Japan, the government passed the “Act on the Safety on Regenerative Medicine” and making revisions to the “Pharmaceutical and Medical device Act” in late 2014, giving a major boost to cell therapy development within Asia. Additionally, the EU has a program for product acceleration – the Adaptive Pathways.
Resource: https://www.bioinformant.com/pharma-investing-in-cell-therapy-companies/